230
Views
5
CrossRef citations to date
0
Altmetric
Original Articles

A new isoflavone glycoside from Abrus cantoniensis

, , , , , , & show all
Pages 588-593 | Received 12 Oct 2018, Accepted 19 Mar 2019, Published online: 13 Apr 2019
 

Abstract

A new isoflavone glycoside named as 8-O-methylrelusin-7-O-β-D-apifuranosyl-(1→2)-β-D-glucopyranoside (1), together with two known compounds, 8-O-methylrelusin-7-O-β-D-glucopyranoside (2) and isobiflorin (3), were isolated from Abrus cantoniensis. The structure of the new compound was elucidated on the basis of spectroscopic methods including extensive 1D NMR, 2D NMR, and HRESIMS. This is the first report of isoflavone from Abrus cantoniensis. Moreover, all isolated compounds were evaluated for their cytotoxicity against SMMC-7721 and MHCC97-H cell lines.

Acknowledgments

We thank Prof. Guo-Gen Liu (Modern Analysis and Testing Centre of Central South University) for NMR measurement and Dr. Hong-Ping Long (The first Hospital of Hunan University of Chinese Medicine) for HRESIMS measurement.

Disclosure statement

No potential conflicts of interest was reported by the authors.

Additional information

Funding

This work was financially supported by the National Natural Science Foundation of China (Nos. 31400311 and 81672887), Natural Science Foundation of Hunan province (No. 2017JJ3213), the Joint Research Fund of QiLu Pharmaceutical Co. Ltd, Opening Fund of Key Laboratory of Chemical Biology and Traditional Chinese Medicine Research (Hunan Normal University), Ministry of Education (No. KLCBTCMR18-06), and Hunan Provincial Innovation Experiment Program for University Students (No. 201810542019).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.